Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IVVD
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
IVVD
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

IVVD Similar Chart Price Prediction

The price of IVVD is predicted to go up -1.62%, based on the high correlation periods with CCEC. The similarity of these two price pattern on the periods is 92.64%.

stocks logo

IVVD

stocks logo

CCEC

Down: -1.62%Similarity: 92.64%

IVVD Revenue Forecast

IVVD EPS Forecast

IVVD FAQs

What is bull’s view on IVVD?

IVVD stock is currently trading at $0.4357, with a bearish sentiment due to insider selling and mixed institutional activity. Despite positive neutralization data for its drug Pemgarda, the stock dropped 5.5%, reflecting weak investor confidence. Analysts maintain a "Strong Buy" with targets up to $10, but near-term headwinds and low RSI suggest caution.

What is bear's view on IVVD?

IVVD stock is currently trading at $0.4357, reflecting a bearish sentiment due to consistent insider selling and mixed institutional activity. The recent 5.5% drop in price, despite positive neutralization data for its drug Pemgarda, indicates weak investor confidence and limited market enthusiasm. With no significant catalysts and ongoing sales headwinds, the stock remains under pressure.

What is IVVD revenue forecast for next quarter？

The market consensus for IVVD's revenue in the upcoming quarter is projected to be approximately $22M USD.

IVVD VS S&P500

Ask Intellectia about IVVD

IVVD Analyst's Forecast

Maxwell Skor

Morgan Stanley

Buy

Price Target

$9.5 → $3.55

Upside

+362.18%

Morgan Stanley lowered the firm's price target on Invivyd to $3.55 from $9.50 and keeps an Overweight rating on the shares. The firm is lowering penetration and sales expectations and "flexing" its view on the odds of success to reflect current sales headwinds, adding that while management appears to be taking the necessary steps to ramp sales, the firm questions if an "updated" antibody is necessary to shift the narrative. Though COVID continues to fade from the headlines, the firm still sees a place for mAbs in the treatment/prevention landscape, the analyst added.
Jason Kolbert

EF Hutton

Strong Buy

Price Target

$9

Upside

+888.9%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free